Cha-ching

MassChallenge Texas wraps up inaugural Houston cohort with top 3 startups and a surprise investment

MassChallenge Texas named its top three startups of its inaugural Houston cohort and the Houston Angel Network made an unexpected investment. Courtesy of MassChallenge Texas

A new-to-Houston global accelerator program just concluded its inaugural cohort, naming three top startups and providing a platform for an unexpected prize — an investment.

MassChallenge Texas didn't originally intend to have monetary prizes for this first program, however, thanks to Houston Angel Network, one lucky startup is walking away from the program $40,000 richer.

HAN, one of Houston's oldest and most active group of angel investors, saw pitch decks from most of the companies in the cohort and then invited seven companies to pitch: Ask DOSS, Celise, DoBrain, NeuroRescue, Noleus Technologies, Sensytec, and Swoovy.

At the September 5 startup showcase event, HAN named Houston-based Sensytec as the winner of the $40,000 investment prize.

The night's other big winners were MassChallenge's top three startups, program: NeuroRescue, Noleus Technologies, and Sensytec, which were selected from the top six startups that were announced a couple weeks in advance.

HAN engaged with the MassChallenge group in a few ways — like mentorship or presenting — but managing director Stephanie Campbell says she knew she wanted to discuss investment opportunities from the very beginning.

"I just think it's really important that when a new group like MassChallenge or any other accelerator come into town that we find ways to fold them into our community and help them be successful," she tells InnovationMap.

All of this year's cohort will receive 18 months of free coworking space — six months at MassChallenge, six months at The Cannon, and six months at Station Houston — and the top three startups will receive automatic entry into another MassChallenge cohort. Because no one won a cash prize from MassChallenge directly, all of the startups are eligible to reapply for another program.

"We wanted to make sure that the companies that went through the shortened version of the program this year have the ability to apply next year to any other program," MassChallenge Texas' Houston managing director, Jon Nordby, says.

Next time around, MassChallenge Texas will likely have a longer program with money on the table. That money would be provided by the organization's corporate partners. The city of Houston has put forth $2.5 million to be dealt out over five years, and Houston-based Reliant Energy has become a central partner to MassChallenge.

"We believe in supporting organizations that are pushing the boundaries and really making an impact in the community as well as the economy and the industry," says Elizabeth Killinger, president at NRG Retail and Reliant.

Killinger says next year she expects Reliant to be just as if not more involved with the process. Campbell too says HAN is interested in continuing its work with MassChallenge, and even sees it setting an example for other angel investors to get involved too.

"We're just planting the seed for the next cohort," Campbell says.

Trending News

Building Houston

 
 

Tvardi Therapeutics Inc. has fresh funds to support its drug's advancement in clinical trials. Photo via Getty Images

A Houston-based clinical-stage biopharmaceutical company has raised millions in its latest round.

Tvardi Therapeutics Inc. closed its $74 million series B funding round led by new investors New York-based Slate Path Capital, Florida-based Palkon Capital, Denver-based ArrowMark Partners, and New York-based 683 Capital, with continued support and participation by existing investors, including Houston-based Sporos Bioventures.

"We are thrilled to move out of stealth mode and partner with this lineup of long-term institutional investors," says Imran Alibhai, CEO at Tvardi. "With this financing we are positioned to advance the clinical development of our small molecule inhibitors of STAT3 into mid-stage trials as well as grow our team."

Through Slate Path Capital's investment, Jamie McNab, partner at the firm, will join Tvardi's board of directors.

"Tvardi is the leader in the field of STAT3 biology and has compelling proof of concept clinical data," McNab says in the release. "I look forward to partnering with the management team to advance Tvardi's mission to develop a new class of breakthrough medicines for cancer, chronic inflammation, and fibrosis."

Tvardi's latest fundraise will go toward supporting the company's products in their mid-stage trials for cancer and fibrosis. According to the release, Tvardi's lead product, TTI-101, is being studied in a Phase 1 trial of patients with advanced solid tumors who have failed all lines of therapy. So far, the drug has been well-received and shown multiple durable radiographic objective responses in the cancer patients treated.

Dr. Keith Flaherty, who is a member of Tvardi's scientific advisory board and professor of medicine at Harvard Medical School, offered his support of the company.

"STAT3 is a compelling and validated target. Beyond its clinical activity, Tvardi's lead molecule, TTI-101, has demonstrated direct downregulation of STAT3 in patients," he says in the release. "As a physician, I am eager to see the potential of Tvardi's molecules in diseases of high unmet medical need where STAT3 is a key driver."

Trending News